共 189 条
[1]
Wilbie D(2019)Delivery aspects of CRISPR/Cas for in vivo genome editing Acc. Chem. Res. 52 1555-1564
[2]
Wang HX(2017)CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery Chem. Rev. 117 9874-9906
[3]
Song X(2021)Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy Adv. Drug Deliv. Rev. 168 158-180
[4]
Lin P(2020)CRISPR-Cas13 inhibitors block RNA editing in bacteria and mammalian cells Mol. Cell 78 850-861
[5]
Gallagher DN(2018)Repair of a site-specific DNA cleavage: old-school lessons for Cas9-mediated gene editing ACS Chem. Biol. 13 397-405
[6]
Haber JE(2016)Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA Nat. Biotechnol. 34 339-344
[7]
Richardson CD(2019)Precision control of CRISPR-Cas9 using small molecules and light Biochemistry 58 234-244
[8]
Gangopadhyay SA(2019)Spatial control of in vivo CRISPR-Cas9 genome editing via nanomagnets Nat. Biomed. Eng. 3 126-136
[9]
Zhu H(2019)Dual-locking nanoparticles disrupt the PD-1/PD-L1 pathway for efficient cancer immunotherapy Adv. Mater. 31 e1905751-740
[10]
Zhang Z(2020)Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer Nat. Med. 26 732-457